$18 Million Series B to Scale Regenerative Medicine Platform
Pandorum Technologies has secured $18 million in Series B funding to advance the clinical development of its programmable regenerative therapies, including Kuragenx. The company will also scale global manufacturing and expand operations across the United States, Japan, and the Middle East.
The round was led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, and members of the Burman Family. Bandana Kankani advised on the transaction and helped structure the investment to support long-term value creation.
Building Tunable, Disease-Modifying Therapies
Founded by Tuhin Bhowmick and Arun Chandru, the Bengaluru-based company operates across India and the United States.
Pandorum’s platform integrates biology, engineering, and computational design to create tunable exosome-based therapies. These therapies aim to reprogram diseased tissue states, including inflammation and fibrosis, toward functional recovery.
Bhowmick described the human body as a system in constant renewal and said the company focuses on restoring biological memory. He stated that the funding will enable translation of scientific research into programmable, disease-modifying therapies, beginning with single-tissue applications and expanding toward multi-tissue repair.
Global Manufacturing Footprint
Pandorum has adopted a distributed manufacturing strategy to support clinical and commercial scale.
The company has partnered with AGC Biologics in Italy to serve the US and European markets. It has also entered a strategic collaboration with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region. Discussions are underway to explore partnerships in the Middle East.
This structure allows Pandorum to position its therapies for multi-regional clinical deployment.
Clinical Leadership Across Continents
Clinical translation efforts are being led by specialists, including Dr. Virender Singh Sangwan of Dr. Shroff’s Charity Eye Hospital, Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine, and Dr. Ramez Haddadin and Dr. Satish Nadig of Northwestern Medicine.
Their involvement signals a focus on rigorous clinical validation as the therapies move toward human application.
Strategic Significance
Regenerative medicine increasingly targets root biological dysfunction rather than symptom management. By developing tunable exosome therapies that aim to modify disease progression, Pandorum positions itself within a high-risk, high-impact segment of biotechnology.
The Series B funding strengthens its ability to move from laboratory research to scaled clinical programs while building global manufacturing and regulatory infrastructure.
